Ignite Creation Date:
2024-05-05 @ 11:43 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00111852
Status:
COMPLETED
Last Update Posted:
2012-03-20
First Post:
2005-05-26
Brief Title:
Study of Desmoteplase International Nonproprietary Name INN in Acute Ischemic Stroke DIAS-2
Sponsor:
Forest Laboratories
Organization:
Forest Laboratories
Study Overview
Official Title:
A Prospective Randomized Double-blind Placebo-controlled Single Bolus Multinational Multi-center Parallel Group Dose-ranging Study of Desmoteplase INN in the Indication of Acute Stroke
Status:
COMPLETED
Status Verified Date:
2012-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate desmoteplase which is a manufactured protein derived from the saliva of the vampire bat in dissolving clots that are blocking the flow of blood through one or more of the blood vessels supplying the brain thereby reopening the blocked blood vessel and allowing blood to flow again in individuals suffering from ischemic stroke
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None